Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab

被引：0
|
作者：
Venturella, Fabio [1 ]
Cancellieri, Giulia [1 ]
Giammanco, Marco [2 ]
Almerico, Anna Maria [1 ]
Aleo, Igor Daniele
Liga, Anastasia Valentina [1 ]
Mortillaro, Francesca [1 ]
Mistretta, Irene [1 ]
机构：
[1] Univ Palermo, Biol Chem & Pharmaceut Sci & Technol Dept, Palermo, Italy
[2] Univ Palermo, Surg Oncol & Stomatol Disciplines Dept, Palermo, Italy
来源：
JOURNAL OF BIOLOGICAL RESEARCH-BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE | 2023年 / 96卷 / 01期
关键词：
cancer; lung; immuno-oncology; Nivolumab; SAFETY;
D O I：
10.4081/jbr.2023.11027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to the new strategy that aims to awaken the immune system to fight cancer cells, there has been a change in the clinical course in the treatment of advanced Non-Small Cell Lung Cancer ( NSCLC). Our study aimed to evaluate the therapeutic efficacy of nivolumab monotherapy in the treatment of patients with advanced stage IIIB/IV non-small cell lung cancer beyond the second line. The results showed a progression-free survival of 7.35 months and an improvement in the quality of life of patients compared to other treatments. In addition, no type 3 and type 4 adverse reactions were detected in patients treated with Nivolumab. We hope that these results, already promising, will lead to an increase in overall survival in the future.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
  • [22] Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice
    Faehling, Martin
    Kopp, Marcel
    Schwenk, Birgit
    Fallscheer, Sabine
    Kramberg, Sebastian
    Eckert, Robert
    ONCOLOGY, 2019, 97 (04) : 228 - 235
  • [23] Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients
    Martin, Paloma
    De Julian, Maria
    Perez Altozano, Javier
    Salvador Coloma, Carmen
    Garcia Sanchez, Jose
    Insa Molla, Amelia
    Martin, Maria
    Mielgo Rubio, Xabier
    Marin, Sara
    Blasco Cordellat, Ana
    Blasco Cordellat, Sara
    Girones, Regina
    Marquez, Diego
    Aparisi, Francisco
    Bas Cerda, Maica
    Juan, Oscar
    Garde-Noguera, Javier
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1328 - S1329
  • [24] Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience
    Bassanelli, M.
    Giannarelli, D.
    Ricciuti, B.
    Magri, V.
    Cecere, F. L.
    Roberto, M.
    Giacinti, S.
    Barucca, V.
    Cassese, R.
    De Giglio, A.
    Scagnoli, S.
    Milella, M.
    Santarelli, M.
    Bengala, C.
    Ruggeri, E. M.
    Marchetti, P.
    Cognetti, F.
    Gelibter, A.
    Cortesi, E.
    Chiari, R.
    Ceribelli, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S611 - S611
  • [25] Rea world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort
    Juergens, R. A.
    Mariano, C.
    Jolivet, J.
    Finn, N.
    Rothenstein, J.
    Reaume, M. N.
    Faghih, A.
    Labbe, C.
    Owen, S.
    Shepherd, F. A.
    Villeneuve, J.
    Romeyer, F.
    Pettersson, F.
    Butts, C.
    CURRENT ONCOLOGY, 2018, 25 (06) : 384 - 392
  • [26] Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
    Lee, Jong Seok
    Lee, Ki Hyeong
    Cho, Eun Kyung
    Kim, Dong-Wan
    Kim, Sang-We
    Kim, Joo-Hang
    Cho, Byoung Chul
    Kang, Jin Hyoung
    Han, Ji-Youn
    Min, Young Joo
    Park, Keunchil
    LUNG CANCER, 2018, 122 : 234 - 242
  • [27] Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer
    Rounds, Amanda
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (21) : 1851 - 1855
  • [28] Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression
    Ricciuti, Biagio
    Genova, Carlo
    Bassanelli, Maria
    De Giglio, Andrea
    Brambilla, Marta
    Metro, Giulio
    Baglivo, Sara
    Dal Bello, Maria Giovanna
    Ceribelli, Anna
    Grossi, Francesco
    Chiari, Rita
    CLINICAL LUNG CANCER, 2019, 20 (03) : 178 - +
  • [29] Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy
    Pirker, Robert
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (09) : 537 - +
  • [30] Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab
    Tabchi, Samer
    Weng, Xiaoduan
    Blais, Normand
    LUNG CANCER, 2016, 99 : 123 - 126
12345